|Bid||187.63 x 100|
|Ask||187.70 x 100|
|Day's Range||187.38 - 190.37|
|52 Week Range||161.09 - 209.22|
|PE Ratio (TTM)||192.43|
|Dividend & Yield||0.91 (0.48%)|
|1y Target Est||N/A|
Shares of Xenetic Biosciences sank on Monday after the Lexington biotech announced a significant setback in its collaboration with Shire plc on a hemophilia drug. Xenetic (XBIO), which has seven employees, announced disappointing results from a Phase 1/2 study of Shire’s SHP656 hemophilia A treatment using Xenetic’s PolyXen technology, which is designed to extend the half-life of drugs. While the technology did extend the half-life of SHP656, and there were no major side effects, Xenetic said the trial had missed its goal of enabling once-weekly dosing.
Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab.